Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS - Free Report) from a buy rating to a hold rating in a research report report published on Friday morning.

Several other research analysts also recently issued reports on EBS. Rodman & Renshaw reissued a "buy" rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Performance

NYSE EBS traded up $0.04 on Friday, reaching $8.10. The stock had a trading volume of 2,476,171 shares, compared to its average volume of 3,152,698. The stock has a market cap of $438.89 million, a P/E ratio of -1.98 and a beta of 1.59. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $15.10. The business's 50-day moving average price is $9.31 and its 200 day moving average price is $8.77. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Institutional Trading of Emergent BioSolutions

Several institutional investors and hedge funds have recently made changes to their positions in EBS. State Street Corp boosted its position in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock worth $15,960,000 after acquiring an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth $9,296,000. American Century Companies Inc. boosted its holdings in shares of Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company's stock worth $6,015,000 after purchasing an additional 623,201 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock valued at $6,192,000 after purchasing an additional 316,700 shares during the period. Finally, Federated Hermes Inc. grew its position in shares of Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company's stock valued at $1,864,000 after purchasing an additional 253,960 shares during the period. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.